医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Build a Global Orthodontic Academic Exchange Platform – The 2022 A-TECH Conference Successfully Held

2022年06月29日 PM05:59
このエントリーをはてなブックマークに追加


 

SHANGHAI

From June 20th to 26th, the 2022 A-TECH Conference was organized by China’s leading digital clear aligner products and service provider, ANGELALIGN TECHNOLOGY INC. Under the theme of “Together to the Future” in this year’s A-TECH, dozens of prestigious orthodontic experts all over the world were invited to present about clinical experience, cutting-edge technologies, and innovative achievements in the field of orthodontics. The A-TECH Conference attracted over 700,000 views online.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005431/en/

Build a Global Orthodontic Academic Exchange Platform -- The 2022 A-TECH Conference Successfully Held (Graphic: Business Wire)

Build a Global Orthodontic Academic Exchange Platform — The 2022 A-TECH Conference Successfully Held (Graphic: Business Wire)

Prof. Ravindra Nanda, from the University of Connecticut, Editor-in-Chief of the “Progress in Orthodontics”, and Adjunct Professor at the Forsyth Institute, was invited as a special guest to address the Conference. In the past 20 years, clear aligner has become very popular as one of the new orthodontic technologies. Prof. Nanda stated that clear aligner treatment and digital dentistry have been a special interest for him in the past few years, and this is where much of his research and clinical experience has been focused. He is looking forward to the presence of ANGELALIGN TECHNOLOGY INC. in the global market.

Digital clear aligner orthodontic treatment is one of the hottest topics in the global dental industry and one of the important factors driving the innovation and growth of the industry. As a well-known clear aligner company, ANGELALIGN TECHNOLOGY INC. provides doctors with a one-stop and comprehensive digital service from patient consultation to completion of orthodontic treatment.

ANGELALIGN TECHNOLOGY INC. has abundant experience in assisting doctors in diagnosis and treatment of complex cases. In years of exploration, ANGELALIGN TECHNOLOGY INC. together with dental experts never ceases to promote cooperation in innovation activities and has been fully integrating digital technology to release a variety of innovative solutions, products, and technologies. This is greatly aided by the company’s interdisciplinary R&D capabilities across five major fields: clinical stomatology, biomechanics, materials science, computer science, and intelligent manufacturing technology. At the same time, the company has also built a reliable technology and data platform to provide more targeted and reliable solutions for complex cases.

Prof. Eric Ting, from the Forsyth Institute, believes that the material evolution and exploration into clear aligner technology are of great significance in tooth extraction treatment. Stiffness and elasticity are two contradictory properties of a material, but all kinds of materials need to reach a balance between them. The masterControl S material newly released by ANGELALIGN TECHNOLOGY INC. in 2021 has six features that are crucial to clear aligner treatment. Its multi-layer structure is integrated with the excellent properties in various materials, which greatly improve the comprehensive treatment efficiency.

According to the report from China Insights Consultancy (CIC) , a renowned consulting firm, ANGELALIGN TECHNOLOGY INC. gained the highest market share of 41.1% in mainland China in 2021.

To enhance academic exploration and cooperation in the field of orthodontics, and to promote the integration of clinical practice and academic research, ANGELALIGN TECHNOLOGY INC. has been organizing the A-TECH Conference since 2014. Every year leading experts are invited to share new exploration fruits and applications in the event for the development of digital stomatology. After 9 years of development, the A-TECH Conference has become a grand event that is under the spotlight in the dental field.

In the 2022 A-TECH Conference, ANGELALIGN TECHNOLOGY INC. unveiled the A7 Speed Premolar Extraction Solution, an upgraded high-efficiency protocol, and iOrtho 10.0. The A7 Speed premolar extraction protocol can synchronize mesialization of posterior teeth with retraction of anterior teeth to improve the overall treatment efficiency in extraction treatment while delivering expected outcomes. iOrtho, developed by ANGELALIGN TECHNOLOGY INC. is an integrated intelligent service platform of digital orthodontics. The 10.0 version features upgrades in five function modules. In particular, the innovative system of remote monitoring in orthodontic treatment enables doctors to easily guide patients to take standard intraoral photos by themselves wherever and whenever they are, so that doctors can monitor patients’ intraoral conditions and provide accurate directions.

Ms. Li Huamin, founder and CEO of ANGELALIGN TECHNOLOGY INC. emphasized in her speech at the conference: “ANGELALIGN TECHNOLOGY INC. adheres to the same belief and love for what we do from the very beginning, and embraces innovative changes. We will focus on the long-term and healthy development of the entire industry based on interdisciplinary-technology integration. And we will continue to promote innovation in products and clinical medical solutions, innovation in digital products, technologies and concepts, and innovation in medical services and organizational management models, to promote the vigorous development of digital orthodontics in the global market.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005431/en/

CONTACT

Contact Person: Lexie Huang

Email: pr@angelalign.com

Website: http://www.angelalign.com/

Telephone: +862156561919

同じカテゴリーの記事 

  • The 11th BioCentury-BayHelix China Healthcare Summit: Reinvent Your Global Drug Development Strategy in Shanghai
  • NAMSA and TERUMO Announce Strategic Outsourcing Partnership
  • Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia
  • NSF Celebrates 80 Years of Improving Human and Planet Health
  • Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease